Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based cancer treatments, has scheduled its third quarter 2024 financial results announcement. The company will release results before market open on November 8, 2024, followed by a conference call and webcast at 8:00 a.m. ET. Domestic investors can dial (877) 407-0792, while international investors can use (201) 689-8263 to participate.
Y-mAbs Therapeutics (Nasdaq: YMAB), una società biofarmaceutica in fase commerciale focalizzata sulla radioimmunoterapia e sui trattamenti antitumorali a base di anticorpi, ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024. L'azienda pubblicherà i risultati prima dell'apertura del mercato l'8 novembre 2024, seguiti da una conferenza telefonica e una trasmissione in diretta alle 8:00 ET. Gli investitori nazionali possono comporre il numero (877) 407-0792, mentre gli investitori internazionali possono utilizzare il numero (201) 689-8263 per partecipare.
Y-mAbs Therapeutics (Nasdaq: YMAB), una empresa biofarmacéutica en etapa comercial enfocada en la radioinmunoterapia y los tratamientos contra el cáncer basados en anticuerpos, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024. La compañía dará a conocer los resultados antes de la apertura del mercado el 8 de noviembre de 2024, seguido de una llamada de conferencia y una transmisión en línea a las 8:00 a.m. ET. Los inversores nacionales pueden marcar el (877) 407-0792, mientras que los inversores internacionales pueden usar el (201) 689-8263 para participar.
Y-mAbs Therapeutics (Nasdaq: YMAB)는 상업 단계의 생물 제약 회사로 방사면역요법 및 항체 기반 암 치료에 집중하고 있으며, 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 회사는 2024년 11월 8일 시장 개장 전에 결과를 발표할 예정이며, 오전 8:00 ET에 회의 전화 및 웹캐스트가 이어질 것입니다. 국내 투자자는 (877) 407-0792로 전화할 수 있고, 국제 투자자는 (201) 689-8263을 사용하여 참여할 수 있습니다.
Y-mAbs Therapeutics (Nasdaq: YMAB), une entreprise biopharmaceutique en phase commerciale spécialisée dans la radioimmunothérapie et les traitements anticancéreux basés sur des anticorps, a programmé l'annonce de ses résultats financiers du troisième trimestre 2024. L'entreprise publiera les résultats avant l'ouverture des marchés le 8 novembre 2024, suivis d'une conférence téléphonique et d'un webinaire à 8h00 ET. Les investisseurs nationaux peuvent composer le (877) 407-0792, tandis que les investisseurs internationaux peuvent utiliser le (201) 689-8263 pour participer.
Y-mAbs Therapeutics (Nasdaq: YMAB), ein biopharmazeutisches Unternehmen in der Kommerzialisierungsphase, das sich auf Radioimmuntherapie und antikörperbasierte Krebsbehandlungen konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 angekündigt. Das Unternehmen wird die Ergebnisse am 8. November 2024 vor Markteröffnung veröffentlichen, gefolgt von einer Telefonkonferenz und einem Webcast um 8:00 Uhr ET. Inländische Investoren können die Nummer (877) 407-0792 wählen, während internationale Investoren die Nummer (201) 689-8263 verwenden können, um teilzunehmen.
- None.
- None.
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.
Conference call and webcast details:
Investors (domestic): Investors (international): | (877) 407-0792 (201) 689-8263 |
To access a live webcast of the update, please use this link.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond, including estimated operating expenses, cash burn and DANYELZA product revenue and sufficiency of cash resources and related assumptions; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; the Company’s plans and strategies, development, commercialization and product distribution plans; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA PRIT Technology and potential benefits and applications thereof; the Company’s mission of delivering better and safer therapies to patients; expectations relating to key anticipated development milestones, including potential expansion and advancement of commercialization and development efforts, including potential indications, applications and geographies, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs, including with respect to timing and results; expectations related to the timing of the initiation and completion of regulatory submissions; additional product candidates and technologies; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of cash and cash equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; the Company’s ability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
When will Y-mAbs (YMAB) release Q3 2024 earnings?
What time is Y-mAbs (YMAB) Q3 2024 earnings call?